The US is the bigger Oncology/Cancer Drugs market: $74.3 Bn against $14.2 Bn in 2023, about 5.2 times as large.
China grows faster: 9.9% a year, against 6.4%. The gap still grows from $60.1 Bn to $101.7 Bn by 2033.
Clinical research: 9,188 active trials in the US, 7,323 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $74.3 Bn | $14.2 Bn |
| Market size, 2033 projected | $138.2 Bn | $36.6 Bn |
| Growth a year (CAGR) | 6.4% | 9.9% |
| Money added, 2023–2033 | $63.9 Bn | $22.3 Bn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $218 | $10 |
| Active clinical trials | 9,188 | 7,323 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Oncology/Cancer Drugs, US or China?
The US is the bigger Oncology/Cancer Drugs market: $74.3 Bn against $14.2 Bn in 2023, about 5.2 times as large.
Which grows faster in Oncology/Cancer Drugs, US or China?
China grows faster: 9.9% a year, against 6.4%. The gap still grows from $60.1 Bn to $101.7 Bn by 2033.
More Oncology/Cancer Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.